MoonLake Immunotherapeutics (MLTX) Payables (2020 - 2026)

MoonLake Immunotherapeutics' Payables history runs 7 years deep, the most recent figure standing at $23.4 million for Q1 2026.

• In Q1 2026, Payables rose 94.74% year-over-year to $23.4 million; the TTM figure through Mar 2026 stood at $23.4 million (up 94.74% YoY), while the FY2025 annual figure was $29.6 million, up 228.66% from the prior year.
• Payables was $23.4 million for Q1 2026 at MoonLake Immunotherapeutics, down from $29.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $29.6 million in Q4 2025 to a low of $150000.0 in Q1 2022.
• Historically, Payables has averaged $8.9 million across 5 years, with a median of $4.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Payables slumped 98.46% in 2022, then soared 2451.6% in 2023.
• A 5-year view of Payables shows it stood at $254972.0 in 2022, then soared by 620.74% to $1.8 million in 2023, then surged by 389.31% to $9.0 million in 2024, then surged by 228.66% to $29.6 million in 2025, then dropped by 20.89% to $23.4 million in 2026.
• The last three Payables figures came in at $23.4 million (Q1 2026), $29.6 million (Q4 2025), and $25.3 million (Q3 2025), per Business Quant data.